Trends & Analysis

Science, Safety, Research, Technology and Cannabis
#Cannabinoid #Medicinal cannabis #Plant-based #Regulatory

Where is the promise for plant-based medicines? Part 1: Cannabis  

In the first part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of medical cannabis in drug discovery. What is the regulatory landscape of medical cannabis?  Medical cannabis is often a first-thought when regarding plant-based medicines, but there remains… Read More

#Exclusive Content #Regulatory #Trends & Analysis

The microbiome
#Drug discovery #Gut microbiome #Microbiome #Precision medicine

The microbiome in precision medicine

Listen to this article on the DDW Podcast: An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. Read More

#Exclusive Content #Trends & Analysis

#Biopharma #Biotech #Clarivate #Collaboration #Investment #Partnership

Biopharma investment drops by nearly 50% in 2022

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The… Read More

#Business & Investment #News #Trends & Analysis

Proteomics
#Genetics / genomics #Mass spectrometry / NMR #Nautilus #Oncology #Protein chemistry / Proteomics #Rare cancers

Democratising proteomics for cancer and beyond

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick, about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. At… Read More

#Exclusive Content #Trends & Analysis

Vascular endothelial growth factor A
#Drug targets #Gilead Sciences #GlobalData #Krystal Biotech #Neurodegenerative disorders #Regenerative Medicine

Regenerative medicine switches to VEGF as top drug target

Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. According to analysts GlobalData, early-stage therapies are now focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development. Surprisingly, the… Read More

#News #Trends & Analysis

#Data #Drug development #Gene sequencing #Genome sequencing #Genomics #Healthcare #Precision medicine #Trusted research environment

Why Trusted Research Environments are key to the future of genomics  

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions. Jack Dix, Head of Healthcare Strategy and Consulting at Kainos, expands.  Genetic… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Animal models #Animal testing #Drug discovery #Drug safety #FDA #Regulatory

What does the FDA animal testing legislation mean for drug discovery? 

As of late December 2022, the US Food and Drug Administration (FDA) no longer needs drugs to be tested in animals to receive approval, according to legislation signed by President Joe Biden1 – the Modernization Act 2.0. This news has been shared widely as a landmark moment, especially in the eyes… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

#AI / data analytics / healthtech / informatics #Clinical trial design #Funding #Psychedelics #Start-ups

What will the 2023 drug discovery landscape look like?

Listen to this article on the DDW podcast: DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean. Virtual clinical trials ‘Virtual’ and ‘technology’ are concepts which are readily… Read More

#Exclusive Content #Trends & Analysis

#Clinical trials #Drug development #EU #FDA #Regulatory

Regulatory affairs in 2023: Key trends and changes  

Dr Julie Warner is Vice President of Regulatory Affairs at global drug development consultancy, Boyds. In this article, she provides her expert insights into the key regulatory developments likely to shape the global drug development industry this year.    Implementation of the EU Clinical Trials… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

Year change from 2022 to 2023
#Clinical trial #Clinical trial design #Covid-19 #Drug delivery #Drug development #Healthcare

Drug discovery predictions: Analysis and insight 

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Clarivate #Drug development #Drug discovery #Market reporting #Personalised medicine #Pharmaceuticals

15 drugs likely to be clinical game-changers

A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented.  Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1… Read More

#Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Computer modelling #DEL #DNA #Drug discovery #Library screening #Target identification

New trends in DNA-encoded library screening

Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL… Read More

#Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity… Read More

#Exclusive Content #Trends & Analysis